Biotechnology company Amgen has chosen West Pharmaceutical Services to use its Daikyo Crystal Zenith (CZ) vials and West FluroTec stoppers, to contain its IMLYGIC (talimogene laherparepvec) therapy.
West senior vice-president and chief technology officer John Paproski said: "West recognises the growing demand for high-quality and technologically advanced containment systems for today’s sophisticated biologic drugs, particularly when there may be challenges of interaction or adsorption related to traditional glass vials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
"Daikyo Crystal Zenith technology represents an important way to address the needs of our customers in this growing biotechnology market."
Amgen Device Technologies vice-president Bill Rich said: "We appreciate the relationship we have with West and how they have worked with us to provide an appropriate container closure solution to address the ultra-cold storage conditions for IMLYGIC."
The CZ container closure system comes with West FluroTec stopper that claims to provide a barrier against extractables without disturbing the seal integrity, which is crucial to maintain the full strength of biological therapies.
The CZ vial can also withstand cold storage temperatures and minimises the breakage risk usually associated with glass.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDaikyo Crystal Zenith cyclic olefin polymer containment and delivery system was designed as a substitute to glass.
The solution has been developed to maintain drug safety, purity and efficacy starting from development through to commercialisation, in a flexible, tailor-made container that is compatible with existing filling technologies, the company claims.
